The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems? (ECTAug)

Jerrry L Lewis

Status: Withdrawn

Conditions: Major Depressive Disorder

Treatments: Drug: Placebo; Drug: memantine

Study type: Interventional

Funder types: Other

Identifiers

NCT00988663

Memantine ECT trial

Details and patient eligibility

About

The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.

Full description

Patients will be assigned randomly either to a treatment group or a placebo groups. All patients in both groups will be receiving standard ECT. The treatment group will receive memantine. All patients will be given a battery of cognitive tests and test of depression before ECT treatments start, after the 6th ECT treatment and after the completions of ECT. An analysis will be performed to see if memantine causes any impact on the response to ECT and prevents memory and cognitive impairment.

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Meets criteria for Major Depressive disorder

Exclusion criteria

• Neurological disease
• Mental retardation
• Seizure disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

0 participants in 2 patient groups, including a placebo group

Memantine arm

Active Comparator group

Description:

Patient receiving ECT and Memantine

Treatment:

Drug: memantine

placebo

Placebo Comparator group

Description:

25 patients receiving ECT will will receive placebo

Treatment:

Drug: Placebo

Drug: memantine